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Abstract
Introduction: The increased bone degradation in osteolytic metastases depends on stimulation of mature
osteoclasts and on continuous differentiation of new pre-osteoclasts. Metalloproteinases (MMP)-13 is expressed in a
broad range of primary malignant tumours and it is emerging as a novel biomarker. Recent data suggest a direct
role of MMP-13 in dissolving bone matrix complementing the activity of MMP-9 and other enzymes. Tumour-
microenvironment interactions alter gene expression in malignant breast tumour cells promoting osteolytic bone
metastasis. Gene expression profiles revealed that MMP-13 was among the up-regulated genes in tumour-bone
interface and its abrogation reduced bone erosion. The precise mechanism remained not fully understood. Our
purpose was to further investigate the mechanistic role of MMP-13 in bone osteolytic lesions.
Methods: MDA-MB-231 breast cancer cells that express MMP-13 were used as a model for in vitro and in vivo
experiments. Conditioned media from MDA-MB-231 cells were added to peripheral blood mononuclear cultures to
monitor pre-osteoclast differentiation and activation. Bone erosion was evaluated after injection of MMP-13-
silenced MDA-MB-231 cells into nude mice femurs.
Results: MMP-13 was co-expressed by human breast tumour bone metastases with its activator MT1-MMP. MMP-
13 was up-regulated in breast cancer cells after in vitro stimulation with IL-8 and was responsible for increased
bone resorption and osteoclastogenesis, both of which were reduced by MMP inhibitors. We hypothesized that
MMP-13 might be directly involved in the loop promoting pre-osteoclast differentiation and activity. We obtained
further evidence for a direct role of MMP-13 in bone metastasis by a silencing approach: conditioned media from
MDA-MB-231 after MMP-13 abrogation or co-cultivation of silenced cells with pre-osteoclast were unable to
increase pre-osteoclast differentiation and resorption activity. MMP-13 activated pre-MMP-9 and promoted the
cleavage of galectin-3, a suppressor of osteoclastogenesis, thus contributing to pre-osteoclast differentiation.
Accordingly, MMP-13 abrogation in tumour cells injected into the femurs of nude mice reduced the differentiation
of TRAP positive cells in bone marrow and within the tumour mass as well as bone erosion.
Conclusions: These results indicate that within the inflammatory bone microenvironment MMP-13 production was
up-regulated in breast tumour cells leading to increased pre-osteoclast differentiation and their subsequent
activation.
Introduction
Bone metastases are the most frequent complication in
breast cancer and lead to severe disease and pain [1].
The development of osteolytic metastases depends on
the tropism of breast cancer cells for bone that is the
result of their ability to migrate, intravasate, extravasate,
and finally to thrive in the metastatic site where osteo-
clasts (OCs) form lytic lesions through the activation of
a complex cascade of morphological and biochemical
changes and release of growth factors sequestered in
the bone matrix. Breast cancer cells that metastasize to
bone establish a tight interaction with the marrow
microenvironment and express several classes of mole-
cules that modulate tumour-bone interplays. Among
these are chemokines and chemokine receptors, growth
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factors, cell adhesion molecules involved in invasion and
metalloproteinases (MMPs) that play a pivotal role in
bone degradation. Recent data suggest a direct role of
MMP-13 in dissolving bone matrix, an osteolytic activ-
ity complementing MMP-9 and other enzymes [2].
MMP-13 was originally identified from a cDNA library
derived from a breast carcinoma [3] and subsequently
found to be produced by tumours of different sources
[4]. It is synthesized as a proenzyme and then activated
by MT1-MMP; indeed both these enzymes co-localize
in several human malignant tumours [5]. The levels of
MMP-13 expression depend on the exposure to a vari-
ety of factors, including hormones and cytokines, pre-
sent in the bone microenvironment, such as PTH and
PTHrP [6,7]. MMP-13 is up-regulated by IL-1 a, -b,
and transforming growth factor (TGF)-b in several
human malignancies [4] and higher expression of
MMP-13 is associated with increased malignancy [8-10]
and shorter overall survival [11,12]. However, while
MMP-13 might represent a poor prognosis marker in
breast carcinomas [13] it seems unlikely that tumour
aggressiveness and bone metastatic lesions solely
depend on its digestive function in the bone microenvir-
onment. Singh and collaborators applied micro-dissec-
tion to breast tumour-bone interface and found that
MMP-13, receptor activator of nuclear factor kappa-B
ligand (RANKL) and integrin binding sialoprotein were
among the most up-regulated genes [14]. They further
demonstrated that down-regulation of MMP-13 with
antisense oligonucleotides significantly reduced bone
destruction.
We thus hypothesized that MMP-13 might be
involved in the complex network of interactions
between tumour and bone cells promoting not only OC
bone-destructive activity, but also OC differentiation.
Here, we demonstrated the functional involvement of
MMP-13 in breast cancer bone metastasis: MMP-13
activated pre-MMP-9 and cleaved galectin-3 on OC pre-
cursors. These actions resulted in stimulation of mature
OC digestive ability as well as in enhanced differentia-
tion of OC precursors.
Materials and methods
Reagents
Recombinant human IL-8, Parathyroid Hormone-related
Protein (PTHrP), Macrophage Colony-Stimulating Fac-
tor (M-CSF) and soluble RANKL were purchased from
Peprotech (London, UK). Recombinant human MMP-13
(catalogue #BML-SE493-0010, lot #3-H4512a) was
obtained from Enzo Life Sciences Inc. (Farmingdale, NY,
USA). MMP-13 specific inhibitor CL-82198 was pur-
chased from Calbiochem (La Jolla, CA, USA), metallo-
proteases generic inhibitor GM6001 was obtained from
Chemicon (Chemicon International, Temecula, CA,
USA). Rabbit polyclonal anti-cow Cytokeratin Wide
Spectrum Screening (catalogue #Z0622) was from Dako
(DakoCytomation Inc, Carpinteria, CA, USA). Mouse
anti-human MMP-13 (catalogue #MAB13442), MMP-9
(catalogue #MAB13458) and MMP-2 (catalogue
#MAB13406) were purchased from Chemicon (Chemi-
con International); mouse anti-human MT1-MMP (cata-
logue #MAB-10765) and mouse anti-human TIMP-1
(catalogue #MAB-12070) were purchased from Immu-
nological Science (Rome, Italy). Mouse anti-human
tubulin (catalogue #T 6074) was obtained from Sigma
(Milan, Italy).
Cells
Human breast adenocarcinoma cell line MDA-MB-231
was maintained in DMEM (BioWhittaker, Lonza, Milan,
Italy) with 10% fetal calf serum (FCS). Human breast
adenocarcinoma cell line MCF7 (ATCC, Rockville, MD,
USA) was maintained in DMEM with 10% FCS, insulin
(10 μg/ml), sodium pyruvate (1 mM) and non-essential
amino acids (0.1 mM).
Human OC cultures
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from buffy coat preparations obtained from the
Blood Bank of the CRO-IRCCS, National Cancer Insti-
tute, Aviano, Italy as previously described [15]. All pro-
cedures were performed with written informed consent
according to the Declaration of Helsinki and used a pro-
tocol approved by the Scientific Director of the Institute.
Cells were grown in Roswell Park Memorial Institute
medium, with 10% FCS, and osteoclastogenesis was
induced for the first three days of culture with human
M-CSF (30 ng/ml) and human RANKL (40 ng/ml). At
Day 4 pre-OCs were cultured with complete medium
containing M-CSF plus RANKL or only with concen-
trated MDA-MB-231 conditioned media.
Conditioned medium (CM) preparation
MDA-MB-231 cells, grown until sub-confluency, were
starved or stimulated with IL-8 (10 ng/ml) or PTHrP
(100 ng/ml) in serum free DMEM, for 24 h. CM were
then collected, centrifuged and concentrated, aliquoted
and stored at -20°C until use.
TRAP staining
To quantify the formation of Tartrate-Resistant Acid
Phosphatase positive (TRAP) multinucleated cells,
PBMC cultures and paraffin-embedded sections were
stained for TRAP using a Leukocyte Acid Phosphatase
kit (Sigma Diagnostics, Milan, Italy), according to the
manufacturer’s instructions. Cells positive for TRAP and
having more than three nuclei were considered as TRAP
positive multinucleated OCs.
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Bone resorption assay
PBMCs were seeded onto calcium phosphate coated
wells (Biocoat, 16-well Osteologic Multitest Slide, BD
Biosciences, Buccinasco, Italy) and cultured for up to
seven days in different culture conditions. Cells were
removed by bleach treatment in order to observe
resorption pits under light microscope.
Computer-assisted morphometric analyses
To quantitatively evaluate OC resorption activity, com-
puter-assisted morphometric analyses were performed
on the images acquired with Nikon Eclipse TS100
microscope (Melville, NY, USA) equipped with a Canon
camera (Canon USA, Inc., Jamesburg, NJ, USA) by
using the ImageJ software (National Institute of Health,
Bethesda, MD, USA) [16]. Images of TRAP or immune-
stained bone sections were captured with a Leica ICC50
camera connected with a Leica DM 750 microscope
(Leica Microsystems Heidelberg, Mannheim, Germany)
equipped with N Plan objective 5×/-0.12 NA, HI-Plan
objective 10×/0.25 NA and objective 20×, all from Leica.
The images were then evaluated by ImageJ computer-
assisted morphometric analysis (National Institute of
Health, Bethesda, MD, USA).
Immunohistochemistry
Human bone metastasis paraffin sections have been
gathered from the Archieves of the Human Pathology
Section, School of Medicine, University of Palermo
(Italy). All the samples were processed and handled
according to the Institutions’ Ethical Guidelines. In
Figure 1C, the histotype and grade status, ER, PR, HER2
and Ki-67 positivity for each patient are reported.
After deparaffination and rehydration using standard
methodologies, primary antibodies were applied. HRP-
conjugated secondary antibodies (Amersham, GE
Healthcare Europe GmbH, Milan, Italy) were used at a
1:100 dilution for one hour at room temperature. Visua-
lization was achieved with diaminobenzidine (DAB) sub-
strate (Vector Laboratories, Burlingame, CA, USA).
Samples were counterstained with hematoxylin, dehy-
drated and mounted.
Western immunoblotting
Supernatants and cell lysates obtained from cell culture
samples were resolved in a SDS-polyacrylamide gel (4 to
20% polyacrylamide gradient) (Bio-Rad; Milan, Italy)
under reducing conditions and transferred to a nitrocel-
lulose membrane. The membranes were saturated with
tris-buffered saline (TBS) buffer (20 mM TRIS and 0.15
M NaCl) containing 0.1% Tween-20 and 5% not fat dry
milk for one hour at room temperature and then incu-
bated with primary antibodies at 4°C overnight. The
membranes were incubated with HRP-conjugated
appropriate secondary antibodies (Amersham, GE
Healthcare Europe GmbH, Milan, Italy) and then
revealed with the ECL Plus chemiluminescence kit
(Amersham, GE Healthcare).
MMP-13 silencing
Human MMP-13 expression was abrogated by stably
transfecting MDA-MB-231 with HuSH 29-mer shRNA
constructs against MMP-13 (Origene Technologies,
Rockville, MD, USA) using Amaxa Cell Line Nucleofec-
tor Kit V (Lonza, Koln, Germany) according to the man-
ufacturer’s instructions. Negative controls included
scrambled non-effective shRNA. The stable clones were
selected and maintained in complete medium supple-
mented with puromycin.
In vivo studies
Procedures involving animals and their care were con-
ducted according to the institutional guidelines in com-
pliance with national laws (D.Lgs. n° 116/92). The Ethic
Committee for Animal Experimentation (CESA) of
CRO-IRCCS, Aviano (Italy) approved the proposed ani-
mal research by protocols #2010/03/05/P1 and #2011/
08/03/P1a. Six-week-old female Foxn1nu nude mice
(Harlan Laboratories, Udine, Italy) were anaesthetized
and the right leg was flexed at 90 degrees. Using a 30
gauge needle a small hole was made into the femoral
bone marrow below the patella and was followed by an
injection of 2 × 105 MDA-MB-231 cells suspended in 5
μl of sterile PBS with a Hamilton syringe. Mice were
divided into subgroups and inoculated as follows with:
PBS (negative control, n = 6); MDA-MB-231 wild type
cells (positive control, n = 8); MDA-MB-231 cells trans-
fected with shRNA vector control (scrambled, n = 11);
and MDA-MB-231 cells transfected with shRNA against
MMP-13 (n = 12). A total of 28 days after treatment
mice were anaesthetized and analyzed by ultrasound
(Siemens-Acuson Sequoia 512, small parts 15 MHz lin-
ear transducer, Siemens AG Medical Solutions, Herlan-
gen, Germany) and computed tomography (CT, GE
Lightspeed 32-slice CT Scanner; GE Healthcare Europe
GmbH, Milan, Italy) in order to observe and quantify
tumour masses and developed osteolytic lesions, respec-
tively. The average volume of tumour masses was calcu-
lated as follows: V = 0.5 × dL × dS
2; dL, larger distance;
dS, smaller distance. All mice were sacrificed and both
left and right femurs were collected for immunohisto-
chemical analysis. Tumours were collected for Western
blotting analysis.
Statistical analysis
Statistical significance of the results was determined by
using the unpaired and paired Student’s t test. A value
of P < 0.05 was considered significant.
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Figure 1 MMP-13 and MT1-MMP are expressed in human breast cancer bone metastasis. A. Representative immunohistochemical images
of MMP-13 and MT1-MMP expression in serial paraffin-embedded human bone metastasis. The positive staining of the two enzymes is
associated to tumour cells as indicated by co-localization with pan-citokeratins (lower panel). Magnification of the insets is provided on the right.
The black arrowheads in the insets of MMP-13 and MT1-MMP immunostaining indicate a cluster of cancer cells in the bone marrow inter-
trabecular space, which express both MMP-13 and MT1-MMP. Scale bar = 100 μm. B. MMP-13 expression in bone metastases from invasive
ductal breast cancer. MMP-13 expression is detected on neoplastic cells with a variable staining intensity ranging from slight (left) to marked
(right). Scale bar = 100 μm. C. MMP-13 and MT1-MMP are associated in metastatic invasive breast cancer cells at tumour-bone interface (red
asterisk). Scale bar = 50 μm. D. Histotype and grade status, ER, PR, HER2 and Ki-67 positivity for each patient whose bone metastases were
examined for MMP-13 and MT1-MMP expression by immunohistochemistry.
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Results
MMP-13 is expressed by breast cancer cells in human
bone osteolytic lesions
Initially we provided the first evidence that MMP-13
protein was expressed in all human metastatic breast
bone lytic lesions and its immunohistochemical reactiv-
ity ranged from weak to intense (n = 8) (Figure 1), irre-
spective of histotype and grade status, ER, PR, HER2
and Ki-67 positivity of the patients (Figure 1C). MT1-
MMP, the MMP-13 natural activator [17], was co-
expressed and co-localized with MMP-13 in bone meta-
static lesions as confirmed by serial pan-cytokeratins
staining (Figure 1).
MMP-13 secretion is modulated by cytokines and
extracellular matrix (ECM) substrates
MDA-MB-231 breast cancer cells secreted higher levels
of MMP-13 than less aggressive MCF7 cells (Figure 2).
Consistent with the MMP-13 levels, also TIMP-1
expression was up-regulated in MDA-MB-231 cells.
MCF7 cells were negative for TIMP-1. We did not
detect MMP-1 (data not shown) nor MMP-2 significant
levels in MDA-MD-231 and MCF-7 supernatants,
whereas MMP-9 expression was observed only in MCF7
cells. Either PTHrP or IL-8 stimulation led to increased
secretion of MMP-13 in both cell lines but in a signifi-
cant manner only in MDA-MB-231 cells (Figure 2).
A panel of ECM molecules was used to evaluate adhe-
sion property of the two breast cancer cell lines that dif-
fer in metastatic potential. The highly metastatic MDA-
MB-231 cells displayed strong adhesive properties to
fibronectin and LN-1 and to substrates typical of the
bone microenvironment (collagens I and III), or of base-
ment membranes (collagen type IV) (Additional file 1,
Figure S1A, B; Additional file 4, Supplementary
materials and methods). The percentage of adherent
cells did not significantly change when a higher detach-
ing force (spin off) was applied. Similar, but slightly
lower, adhesion forces were detected in the non-invasive
MCF7 cell line (Additional file 1, Figure S1A, B; Addi-
tional file 4, Supplementary materials and methods). On
the contrary, while MDA-MB-231 cells preferentially
migrated on fibronectin and collagens, MCF7 migrated
very poorly or not at all on all the substrates tested
(Additional file 1, Figure S1C, D). Since bone metastatic
lesions are accompanied by inflammatory infiltrates in
which IL-8 stimulates OC-mediated bone erosions [18]
we found that IL-8 stimulation increased significantly
the migration of MDA-MB-231 cells on collagens com-
pared to the other ECM molecules: we detected only
about 30% increased migration on fibronectin versus
55% increase on collagen I. Moreover, MMP-13 expres-
sion was up-regulated in MDA-MB-231 cells by adhe-
sion to collagen III and IL-8 treatment potentiated this
effect particularly in cells adherent to collagens I and IV
(Additional file 1, Figure S1E; Additional file 4, Supple-
mentary materials and methods). Based on the above
findings we used MDA-MD-231 for all the following
experiments.
MMP-13 is involved in osteoclastogenesis as well as in OC
activity
Since MDA-MB-231 cells secreted large amounts of
MMP-13 and can metastasize to bone where they
induce osteolytic lesions, we investigated the role of
MMP-13 in OC differentiation treating M-CSF or M-
CSF plus RANKL primed PBMCs with CM from MDA-
MB-231. When M-CSF alone was used for the first
three days, the addition of CM determined only a slight
increase in TRAP-positive multinucleated cells; in the
Figure 2 MMP expression in MDA-MB-231 and MCF7 cells. A. MMP expression in MDA-MB-231 and MCF7 cells, stimulated with PTHrP or IL-8
for 24 h in serum free medium. Protein extracts of cellular lysates (for detection of MT1-MMP) and supernatants (for detection of MMP-13, MMP-
9, MMP-2 and TIMP-1) were loaded for Western blotting analysis. Representative blottings are reported. Tubulin was used as a loading control. B.
Quantification of Western blot analysis for MMP-13 expression by QuantityOne software (Bio-Rad; Milan, Italy). Mean values (± SD) of MMP-13
relative expression levels of three different experiments are reported. *P < 0.05; **P < 0.01; NS, not significant.
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presence of M-CSF plus RANKL the number of multi-
nucleated TRAP positive cells was higher than in con-
trol cultures. The effect was more pronounced with the
addition of CM obtained from MDA-MB-231 cells sti-
mulated with IL-8 and PTHrP (IL-8-CM and PTHrP-
CM) (Figure 3A, B). The size of multinucleated OCs
also was abundantly increased in cells cultured with
CM, especially with IL-8 and PTHrP-CM (Figure 3A).
Consequently, resorption was more pronounced in cul-
tures treated with CM or IL-8 and PTHrP-CM (Figure
3C, D). We hypothesized that the extent of resorption
could directly depend on the amount of MMP-13
Figure 3 Breast cancer CM increase osteoclastogenesis and bone resorption. A. Human OC precursors were primed with M-CSF and
RANKL or with M-CSF alone for three days and then cultured for another four days with the addition of CM from MDA-MB-231 cells (CM), IL-8-
or PTHrP-stimulated cells (IL-8-CM, PTHrP-CM) or with IL-8 (10 ng/ml) and PTHrP (100 ng/ml) alone. Representative images of TRAP staining are
shown and the total number of multinucleated TRAP positive cells per well of a 24-well plate is provided (B). Mean values ± SD of three
experiments are reported. C. PBMCs were seeded on Biocoat matrices to evaluate resorption activity. Representative images of resorption pits are
shown and the quantification of the total resorption area per well of a 96-well plate is reported as mean values ± SD of three experiments (D).
*P < 0.05; **P < 0.02; NS, not significant.
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released in the supernatant, since the augmented MMP-
13 levels obtained in PTHrP-CM but also in IL-8 trea-
ted cells (see Figure 2) increased not only the number
of pits but also resulted in larger digestion areas. The
addition of IL-8 or PTHrP alone to PBMC cultures in
the presence of M-CSF plus RANKL did not signifi-
cantly increase the number of multinucleated TRAP
positive cells (Figure 3A, B).
To determine if MMP-13 expressed by tumour cells
and the increased OC differentiation and activation
were causally linked, we used two approaches to abolish
MMP-13 expression.
First, in the presence of the MMP-13 specific inhibitor
CL-82198 [19,20] or of the generic MMP activity inhibi-
tor GM6001 a lower number of multinucleated TRAP
positive cells was detected (Figure 4A, B). The inhibitory
Figure 4 OC differentiation and resorption are potentiated by the presence of MMPs. PBMCs were cultured on plastic (A) or on Biocoat
matrices (C) with M-CSF and RANKL for three days and then with the addition of CM, PTHrP-CM or IL-8-CM for further four days. MMP inhibitors
(10 μM GM6001 and 10 μg/ml CL-82198) were added at Day 1 of culture. TRAP staining was performed at Day 7. Representative images are
shown in (A) and the number of multinucleated TRAP positive cells per field (10×) is reported in (B) as the mean ± SD. 8 fields for each
experiment (n = 3) were examined. C. Representative fields of resorption activity. D. Quantification of the resorbed area is reported as the mean
values ± SD of the percentage eroded area per well of a 96-well plate. Three experiments were evaluated.
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effect of GM6001 was very strong and almost totally
blocked OC differentiation. Consequently, MMP inhibi-
tors reduced in vitro bone resorption, suggesting that
this OC activity was due to a large extent to MMPs; in
fact, CL-82198 partially and GM6001 fully inhibited
resorption (Figure 4C, D). While the specific MMP-13
inhibitor was much less effective, it still reduced the size
of resorption pits in OC cultures treated with PTHrP-
and IL-8-CM (Figure 4C, D and data not shown).
In the second approach, MMP-13 expression was sup-
pressed by specific shRNA sequences. OC precursors
were treated with CM derived from control or MDA-
MB-231 cells transfected with scrambled shMMP-13 or
with CM from one of the clones displaying an almost
complete protein silencing (clone #1) (Figure 5A). Only
the treatment with CM derived from specific MMP-13
shRNA significantly reduced OC number (Figure 5B).
Then, M-CSF and RANKL primed PBMCs were co-
Figure 5 MMP-13 potentiates OC differentiation. A. Western blotting analysis of MMP-13 expression in supernatants of wild type MDA-MB-
231, scrambled shRNA and MMP-13 shRNA (clones #1, #2, #3 and #4) cells. B. PBMCs were primed with RANKL and M-CSF (primed pre-OC) for
three days and then cultured with the addition of CM, obtained from wild type (MDA-MB-231 CM), scrambled shRNA (scrambled CM) and MMP-
13 shRNA cells (clone #1) (MMP-13-shRNA CM) for further four days. The graph reports the mean ± SD of the number of multinucleated TRAP
positive cells per field (20×). 10 fields for each experiment (n = 3) were examined. C. PBMCs were primed with M-CSF and RANKL for three days
and then co-cultured with wild type, Scrambled and MMP-13 silenced MDA-MB-231 cells (clone #1) for further four days. Representative images
of TRAP staining and their magnifications are reported. D. Recombinant human MMP-13 (10 ng/ml) was added alone or together with its
specific inhibitor CL-82198 (10 μg/ml) to PBMCs primed with M-CSF and RANKL for three days. Representative images of TRAP staining of OC
cultures at Day 7 are shown. The graph reports the mean ± SE of the number of multinucleated TRAP positive cells per field (20×). Five fields for
each experiment (n = 3) were examined. *P < 0.05; NS, not significant. E. Western blotting analysis of galectin-3 in extracts of PBMCs cultured in
the presence of RANKL and M-CSF for two, five or seven days (left panel) and of pre-OC cultured with CM as reported in (B) (right panel). F.
Western blotting analysis for pro- and active MMP-9 forms in primed pre-OC treated as reported in (C) with silenced (sh#1 and sh#2) or
Scrambled (scr#1 and scr#2) clones.
Pivetta et al. Breast Cancer Research 2011, 13:R105
http://breast-cancer-research.com/content/13/5/R105
Page 8 of 15
cultured with MDA-MB-231 cells. TRAP staining of
seven-day-old co-cultures showed that abrogation of
MMP-13 expression nearly fully abolished the enhanced
osteoclastogenesis (Figure 5C). Silenced clones were also
stimulated with IL-8 or PTHrP and the corresponding
CM added to OC precursors. A slight even, if not signif-
icant, increase in osteoclastogenesis was detected
(Additional file 2, Figure S1A; Additional file 4, Supple-
mentary materials and methods), indicating that stimu-
lation of IL-8 or PTHrP can induce some MMP-13
secretion in not fully silenced cells. In conclusion,
MMP-13 shRNA CM was unable to increase the num-
ber of TRAP-positive multinucleated cells compared to
control and “scrambled” CM suggesting that MMP-13
effectively potentiated OC differentiation.
From the previous series of experiments we con-
cluded that MMP-13 was involved in both differentia-
tion and activation of OCs. Furthermore, the addition
of human recombinant MMP-13 to the PBMC cultures
was able to enhance the number of TRAP multinu-
cleated cells, reinforcing the evidence that this metallo-
proteinase could potentiate OC differentiation process
(Figure 5D).
Next, the mechanism of this involvement was inves-
tigated on the basis of the following evidence: 1) galec-
tin-3, a known inhibitor of osteoclastogenesis [21], is a
substrate of MMP-13 in vitro [22]; 2) MMP-13 regu-
lates the activation of pre-MMP-9 [14] that is asso-
ciated with OC differentiation process [23]. Western
blotting of protein extracts revealed that galectin-3 was
degraded during ostoclastogenesis (Figure 5E, left
panel). When pre-OCs were treated with CM obtained
from both control and scrambled MMP-13 MDA-MB-
231 cells, galectin-3 resulted fragmented in protein
extracts; on the contrary, degradation was absent when
MMP-13 shRNA CM were used (Figure 5E, right
panel). Finally, we analyzed the presence of MMP-9 in
the supernatants of the co-cultures: the active form of
MMP-9 was detected to a much greater extent in dif-
ferentiated OC cultures and it was almost totally
absent when silenced cells were added to pre-OCs
(Figure 5F).
MMP-13 increases osteoclastogenic potential in vivo
Next, the in vitro MMP-13 silenced breast tumour
model results were checked in vivo. First, we excluded
the transfection with shRNAs influenced cell growth.
All cells examined displayed growth curves with a very
similar trend (Additional file 2, Figure S1B; Additional
file 4, Supplementary materials and methods). Conver-
sely, only MMP-13 shRNA clones migrated significantly
less towards collagen type I respect to WT and
scrambled MMP-13 cells, indicating that MMP-13 silen-
cing was effective [24-26] (Additional file 2, Figure
S1C; Additional file 4, Supplementary materials and
methods).
WT and transfected cells were inoculated into the
femurs of six-week-old nude mice and after one month
ultrasound ecography and CT scans were performed to
evaluate tumour mass and extent of skeletal erosion,
respectively. In accord with the in vitro growth curves, the
in vivo growth of MDA-MB-231 was independent of
MMP-13 expression since the tumour masses developed
from the different clones injected were of similar size
(Figure 6A-C). On the contrary, the CT analysis confirmed
the role of MMP-13 produced by tumour cells in osteoly-
sis. In accord with the levels of MMP-13 expression in the
tumours transfected with the different shRNAs (Figure
6B), the extent of bone erosion was much higher in lesions
produced by WT and scrambled MMP-13 cells than that
of MMP-13 shRNA clones (Figure 6D, E,Additional file 3,
Figure S1). The immunohistochemical analysis and TRAP
staining of mouse femurs showed that the expression of
MMP-13 directly correlated with the number of TRAP
positive cells (Figure 7A) that were present not only in the
proximity of bone erosion (Figure 7B) but also in bone
marrow (Figure 7C).
Discussion
A key finding of the present study is that MMP-13 plays a
crucial role in the microenvironment of bone metastases.
MMP-13 released by breast tumour cells following stimu-
lation with IL-8 or PTHrP played an amplifier role in the
bone metastatic microenvironment by increasing and sus-
taining the erosion process of OCs. MMP-13 enhanced
differentiation of pre-OCs, activated pro-MMP-9 released
from OCs and cleaved galectin-3 expressed on OC cell
surface, thus blocking its inhibitory activity on osteoclasto-
genesis. It has been previously reported that up-regulation
of MMP-13 in mouse bone lesions is important for regula-
tion of tumour-induced osteolysis. Knockdown of MMP-
13 expression led to a significant reduction in the number
of activated OCs and hence bone destruction [14]. Our
present data, based on the use of specific MMP-13 shRNA
in in vitro and in vivo experiments, identify a novel specific
function of this enzyme in OC precursor differentiation.
The relevance of the present experimental model data was
supported by the finding that MMP-13 and MT1-MMP
were co-expressed in human metastatic breast tumour foci
in the bone.
MMP-13 is regulated by several pro-inflammatory fac-
tors, such as IL-1 and TNF-a [4]. Here we showed that
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Figure 6 MMP-13 increases osteoclastogenic potential in vivo. WT and transfected cells were inoculated into the femurs of 6 weeks-old
nude mice. Volume (A) and MMP-13 expression (B) of the tumours developed one month after the inoculation of WT, scrambled and shRNA
MDA-MB-231 cell clones. Data in (A) are expressed as the mean ± SE (WT, n = 8; Scrambled, n = 11; MMP-13-shRNA, n = 12). C. Representative
ultrasound images of WT, scrambled and shRNA #1 clones after one month from injection into nude mice. The basal skeletal condition is
represented by PBS inoculation. Red and yellow dotted lines approximately label tumour mass and bone profile, respectively. D. Representative
images and their magnification of CT analysis of skeletal lesions produced by MDA-MB-231 cell clones injected into nude mice. E. The graph
shows the level of femur erosion, calculated as follows: (1- (length of the undamaged femur injected/length of untreated counterpart)) × 100.
Results are the mean ± SE (WT, n = 8; Scrambled, n = 11; MMP-13-shRNA, n = 12). *P < 0.05; NS, not significant.
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Figure 7 MMP-13 expression is associated with the presence of TRAP positive cells within bone marrow and tumour. A. Histology,
immunohistochemical staining for MMP-13 and pan CK, and TRAP staining were performed on femurs injected with PBS, wild type, Scrambled
and MMP-13 shRNA MDA-MB-231 cell clones. Representative images are shown for each conditions. The number of TRAP positive cells at
tumour/bone interface (B) and in the bone marrow infiltrated by tumour cells (C) are reported. Six sections of 10 × fields of four mice for each
treatment were examined. Data are expressed as mean ± SD. *P < 0.05. Scale bars = 100 μm.
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MMP-13 was up-regulated in MDA-MB-231 cells also
by IL-8. This chemokine attracts monocytes and OC
precursors and promotes angiogenesis. In the metastatic
inflammatory bone microenvironment IL-8 increases
OC motility to new resorption sites [27]. Several studies
have shown that under severe inflammatory conditions
the elevated concentrations of MMP-13 are often
matched by increased levels of interleukins, especially
IL-8 [18,28-30]. This cytokine was suggested to regulate
MMP-13 secretion in osteoarthritic articular chondro-
cytes. We found that the addition of CM obtained from
MDA-MB-231 cells after IL-8 treatment to pre-OC cul-
tures led to the increased number and size of OCs and
to a more pronounced bone resorption.
Alteration in migration properties is perceived to
play a pivotal role in the multi-step process that
impacts on tumour cell-organ tropism and coloniza-
tion. Thus, MDA-MB-231 cells very strongly adhered
to both fibronectin and collagens and this could at
least in part explain the tropism of breast tumour cells
for bone, that is the richest tissue in collagen type I
and III; however, migration on collagen type I was
increased to a much greater extent by IL-8 compared
to migration on fibronectin. The fact that IL-8-stimu-
lated MDA-MB-231 cells migrated more on collagens
and also were able to produce higher levels of MMP-
13, sustains the hypothesis that bone microenviron-
ment favours the production of lytic enzymes through
both inflammatory cytokines and ECM components of
the bone stroma.
Consistent with the findings that MMPs, produced by
tumour cells, enhance OC degradation by prior removal
of the overlying unmineralized layer [31], MMP-13
released by PTHrP or IL-8 primed MDA-MB-231 cells
affected bone resorption (that is, OC activation and
function), an activity that was fully inhibited by
GM6001 and partially by CL-82198. It has been already
demonstrated that MMP-9 stimulates unmineralized
cartilage degradation in the presence of MMP-13
[20,23]. By the use of CL-82198, we confirmed a conver-
gent role of MMP-9 and -13 in bone degradation. OC
size is directly linked to resorptive activity [32] and the
presence of MMP-13 resulted in the generation of OCs
larger in size and displaying a greater resorption capa-
city. The MMP-13 silencing persisted also following in
vivo inoculation, and resulted not only in a diminished
bone erosion in the presence of tumour masses of simi-
lar size but also in a significant reduction of TRAP
positive cells in bone marrow and within the tumour
masses.
The role of MMP-13 on osteoclastogenesis could be
explained as a cooperative effect with MMP-9. Among
MMPs, the principal player is MMP-9 secreted by
monocytes and OCs with MMP-13 derived from
tumour cells acting as modulator in some specific
steps of the differentiation process. MMP-13 regulates
the activation of pre-MMP-9, which recruits OCs dur-
ing development of long bones [23]. Mechanistically,
this is an important step since the ensuing cleavage of
galectin-3, a known suppressor of osteoclastogenesis
[21], reduces its inhibitory function. The finding that
galectin-3 is a substrate of MMP-13 in vitro [22]
implies that MMP-13 could cleave galectin-3 expressed
on OC precursors to counter its inhibitory effect in
vivo but this mechanism remains a matter of specula-
tion. Consistent with this hypothesis, degradation of
galectin-3 became more evident in vitro following the
addition of CM containing larger amounts of MMP-13.
Another explanation for MMP-13 effect on osteoclas-
togenesis could be an indirect action on osteoblasts; it
is often thought that MMPs and other osteogenic fac-
tors secreted by breast cancer cells activate osteoclasts
through osteoblasts by changing the expression of
RANKL and/or OPG [33]. Whether this possibility
could explain the MMP-13 effect remains to be
demonstrated in vivo.
Conclusions
Several key cell types are involved in breast carcinoma
bone metastasis: cancer and inflammatory cells, osteo-
blasts and OCs. We suggest that IL-8 and/or PTHrP
produced by inflammatory cells or osteoblasts stimu-
late secretion of MMP-13 by breast tumour cells;
MMP-13 then indirectly induces OC differentiation by
activating pro-MMP-9 that, together with MMP-13
itself, could contribute to cleave the osteoclastogenesis
inhibitor galectin-3, and cooperates with MMP-9 to
directly degrade bone matrix (Figure 8). Clinical trials
designed to test the efficacy of biologically active MMP
inhibitors in a range of tumour types have been disap-
pointing but not entirely unexpected considering all
the diverse functions of the various MMPs, since only
non-selective MMP inhibitor drugs entered trials.
Based on the present study, a clinically usable specific
MMP-13 inhibitor could be suggested as a new anti-
resorptive therapeutic agent.
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Additional material
Additional file 1: Adhesion and migration profiles of MDA-MB-231
and MCF7 cells. Additional information on cancer cell lines.
Additional file 4: Supplementary materials and methods. Additional
information on experimental conditions.
Additional file 2: In vitro behaviour of MMP-13 silenced cells.
Additional information on MMP-13 silenced cell properties.
Additional file 3: Histological appearance of bone destruction at
low magnification. Representative composed images of mouse femurs
after injection of cell clones.
Abbreviations
CM: conditioned media; DAB: diaminobenzidine; ECM: extracellular matrix;
MMP: metalloproteinase; OC: osteoclast; PBMCs: peripheral blood
Figure 8 Proposed model for the role of MMP-13 in lytic bone metastases. MMP-13, secreted by breast tumour cells, after stimulation of
ECM components or factors (IL-8, produced by inflammatory cells or osteoblasts, or PTHrP, secreted by tumour and stromal cells), could
contribute to osteolysis cooperating with enzymes secreted by OCs (in particular MMP-9 present in the bone microenvironment) for matrix
degradation. The effect on bone erosion could be enhanced by the indirect action of MMP-13 on the differentiation of pre-OCs and their
activation. MMP-13 activates pro-MMP-9 which is known to recruit OCs and alone or together with MMP-9 cleaves galectin-3, thus blocking its
inhibitory effect on osteoclastogenesis.
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mononuclear cells; PBS: phosphate buffered saline; TBS: tris-buffered saline;
TRAP: Tartrate-Resistant Acid Phosphatase positive.
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